Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01439204 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb
A Phase 1 study of Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 223
- Enrollment target
- 1
- Study location
NCT01439204 is a Phase 1 study of Rheumatoid Arthritis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 223 participants, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01439204, a Phase 1 study of Rheumatoid Arthritis, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 223 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether the blood levels of Abatacept (BMS-188667) drug product manufactured at Lonza Biologics and the Devens, MA facility of Bristol-Myers Squibb are comparable in healthy subjects
Conditions Studied
Interventions
- BIOLOGICAL Abatacept (BMS-188667)
Study Locations (1)
Nebraska
- Icon Clinical Pharmacology Unit, Llc - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01439204
The ClinicalTrials.gov registry entry for NCT01439204 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (95% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Abatacept (BMS-188667) is the first listed.
NCT01439204 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT01439204 about?
NCT01439204 is a clinical study titled "Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb". The purpose of this study is to determine whether the blood levels of Abatacept (BMS-188667) drug product manufactured at Lonza Biologics and the Devens, MA facility of Bristol-Myers Squibb are comparable in healthy subjects
What is the current status of trial NCT01439204?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 223 participants. The study started on 2011-10. Estimated completion is 2012-02.
What conditions does trial NCT01439204 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT01439204?
The interventions under investigation include: Abatacept (BMS-188667) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01439204?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01439204 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of GS-0151 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
-
MAD Study of IA-14069
RECRUITING · Phase 1
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
RECRUITING · Phase 1
-
Imaging of Lymphatic Vessels in People with Rheumatoid Arthritis (RA)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.